Beneficial effects of L-carnitine in myoblastic C2Cl2 cells interaction with zidovudine

被引：26

作者：

Georges, B ^{[1
]}

Galland, S ^{[1
]}

Rigault, C ^{[1
]}

Le Borgne, F ^{[1
]}

Demarquoy, J ^{[1
]}

机构：

[1] Univ Bourgogne 1, UPRES Lipides & Nutr, Fac Gabriel, F-21000 Dijon, France

来源：

BIOCHEMICAL PHARMACOLOGY | 2003年 / 65卷 / 09期

关键词：

L-carnitine; zidovudine; C2Cl2; transporter; skeletal muscle; lipid metabolism;

D O I：

10.1016/S0006-2952(03)00110-2

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

L-Carnitine is a key molecule in the transfer of fatty acid across mitochondrial membranes. Bioavailable L-Carnitine is either provided by an endogeneous biosynthesis or after intestinal absorption of dietary items containing L-carnitine. After intestinal absorption or hepatic biosynthesis, L-carnitine is transferred to organs whose metabolism is dependent upon fatty acid oxidation, such as skeletal muscle. To cross the muscle plasma membrane, there are several transporters involved. Among those transporters, OCTN2 is actually the only one to have been clearly characterized. Zidovudine is a commonly used inhibitor of human immunodeficiency virus (HIV) replication. Zidovudine has many side effects, including induction of myopathy characterized by a metabolic mitochondria dysfunction and a diminution of the Muscle L-carnitine content. In this study, we described the characteristics of L-carnitine transport in C2C12 cells. We also demonstrated that zidovudine inhibited the L-carnitine transporter. This inhibition led to a significant reduction of the muscle cell growth. In C2C12 cells, the supplementation of L-carnitine prevented the effects of zidovudine and restored the normal cell growth. (C) 2003 Elsevier Science Inc. All rights reserved.

引用

页码：1483 / 1488

页数：6

共 17 条

[1]

DEPLETION OF MUSCLE MITOCHONDRIAL-DNA IN AIDS PATIENTS WITH ZIDOVUDINE-INDUCED MYOPATHY [J].

ARNAUDO, E ;

DALAKAS, M ;

SHANSKE, S ;

MORAES, CT ;

DIMAURO, S ;

SCHON, EA .

LANCET, 1991, 337 (8740) :508-510

[2]

Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells [J].

Benbrik, E ;

Chariot, P ;

Bonavaud, S ;

AmmiSaid, M ;

Frisdal, E ;

Rey, C ;

Gherardi, R ;

BarlovatzMeimon, G .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 149 (01) :19-25

[3]

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway [J].

Brinkman, K ;

ter Hofstede, HJM ;

Burger, DM ;

Smeitinkt, JAM ;

Koopmans, PP .

AIDS, 1998, 12 (14) :1735-1744

[4]

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome [J].

Carr, A ;

Miller, J ;

Law, M ;

Cooper, DA .

AIDS, 2000, 14 (03) :F25-F32

[5]

Adverse effects of antiretroviral therapy [J].

Carr, A ;

Cooper, DA .

LANCET, 2000, 356 (9239) :1423-1430

[6]

Chariot P, 1991, Neuromuscul Disord, V1, P357, DOI 10.1016/0960-8966(91)90122-9

[7]

DETERMINATION OF THE BLOOD LACTATE-PYRUVATE RATIO AS A NONINVASIVE TEST FOR THE DIAGNOSIS OF ZIDOVUDINE MYOPATHY [J].

CHARIOT, P ;

MONNET, I ;

MOUCHET, M ;

ROHR, M ;

LEFAUCHEUR, JP ;

DUBREUILLEMAIRE, ML ;

CHOUSTERMAN, M ;

GHERARDI, R .

ARTHRITIS AND RHEUMATISM, 1994, 37 (04) :583-586

[8]

ZIDOVUDINE-INDUCED MITOCHONDRIAL MYOPATHY IS ASSOCIATED WITH MUSCLE CARNITINE DEFICIENCY AND LIPID STORAGE [J].

DALAKAS, MC ;

LEONMONZON, ME ;

BERNARDINI, I ;

GAHL, WA ;

JAY, CA .

ANNALS OF NEUROLOGY, 1994, 35 (04) :482-487

[9]

Functional characterization of intestinal L-carnitine transport [J].

Durán J.M. ;

Peral M.J. ;

Calonge M.L. ;

Ilundáin A.A. .

The Journal of Membrane Biology, 2002, 185 (1) :65-74

[10]

Carnitine transport into muscular cells. Inhibition of transport acid cell growth by mildronate [J].

Georges, B ;

Le Borgne, F ;

Galland, S ;

Isoir, M ;

Ecosse, D ;

Grand-Jean, F ;

Demarquoy, J .

BIOCHEMICAL PHARMACOLOGY, 2000, 59 (11) :1357-1363

← 1 2 →